Skip to content 
Millions of people with asthma are being urged to review their treatment after doctors issued updated, “landmark” guidelines that could significantly change how the condition is managed worldwide. The focus is on the widely used blue inhaler, which has been a mainstay of asthma care for decades.
Health experts now warn that relying on blue inhalers alone may no longer be the safest approach for managing asthma long-term.
Why doctors are raising concerns
The blue inhaler, known medically as a short-acting reliever inhaler, works by quickly opening the airways during an asthma attack. While it provides fast relief, it does not treat the underlying inflammation in the lungs.
New guidelines from major respiratory bodies such as NICE and GINA highlight that this can create a hidden risk: people may feel temporarily better while the underlying asthma continues to worsen.
Doctors now say overuse of blue inhalers is strongly linked to a higher risk of asthma attacks, hospital admissions, and in severe cases, even death.
What the “landmark” guidelines are changing
The new recommendations encourage a major shift away from blue-inhaler-only treatment and toward combination inhalers that contain both:
- A fast-acting reliever medicine
- A steroid that reduces airway inflammation
These are often referred to as AIR (Anti-inflammatory Reliever) or MART (Maintenance and Reliever Therapy) treatments.
Unlike traditional blue inhalers, these newer treatments address both symptoms and the root cause of asthma, helping to prevent attacks rather than just relieve them.